Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

21.35

Margin Of Safety %

Put/Call OI Ratio

4.89

EPS Next Q Diff

-0.01

EPS Last/This Y

-0.2

EPS This/Next Y

0.87

Price

8.3

Target Price

27.88

Analyst Recom

1

Performance Q

-32.68

Relative Volume

0.76

Beta

0.85

Ticker: KALV




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19KALV8.094.430.006379
2024-12-20KALV8.354.360.206364
2024-12-23KALV8.815.540.136035
2024-12-24KALV8.765.530.006037
2024-12-26KALV8.825.530.006037
2024-12-27KALV8.535.510.006040
2024-12-30KALV8.45.470.006047
2024-12-31KALV8.484.13112.634801
2025-01-02KALV8.865.060.005708
2025-01-03KALV9.025.050.005710
2025-01-06KALV8.674.97999.995725
2025-01-07KALV8.764.970.005727
2025-01-08KALV8.264.96999.995729
2025-01-09KALV8.244.96999.995729
2025-01-10KALV7.874.93999.995702
2025-01-13KALV7.554.95999.995722
2025-01-14KALV7.414.95999.995722
2025-01-15KALV7.884.95999.995722
2025-01-16KALV8.264.950.335725
2025-01-17KALV8.314.89999.995739
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19KALV8.09-4.4- -3.65
2024-12-20KALV8.37-4.9- -3.65
2024-12-23KALV8.83-4.9- -3.65
2024-12-24KALV8.76-4.9- -3.65
2024-12-26KALV8.83-4.9- -3.65
2024-12-27KALV8.54-4.9- -3.65
2024-12-30KALV8.41-4.9- -3.65
2024-12-31KALV8.47-4.9- -3.65
2025-01-02KALV8.84-4.9- -3.65
2025-01-03KALV9.01-4.9- -3.65
2025-01-06KALV8.67-4.9- -3.65
2025-01-07KALV8.79-4.9- -3.65
2025-01-08KALV8.24-4.9- -3.65
2025-01-09KALV8.24-4.9- -3.65
2025-01-10KALV7.86-4.9- -3.65
2025-01-13KALV7.54-4.9- -3.65
2025-01-14KALV7.42-4.9- -3.65
2025-01-15KALV7.86-4.9- -3.65
2025-01-16KALV8.23-4.9- -3.65
2025-01-17KALV8.30-4.9- -3.64
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19KALV-0.555.6020.94
2024-12-20KALV-0.555.6020.94
2024-12-23KALV-0.545.6120.94
2024-12-24KALV-0.545.6120.94
2024-12-26KALV-0.565.6120.71
2024-12-27KALV-0.555.6120.71
2024-12-30KALV-0.575.6120.71
2024-12-31KALV-0.575.6120.71
2025-01-02KALV-0.555.6120.71
2025-01-03KALV-0.555.6120.71
2025-01-06KALV-0.545.6020.71
2025-01-07KALV-0.545.6020.71
2025-01-08KALV-0.555.6020.71
2025-01-09KALV-0.555.6020.71
2025-01-10KALV-0.555.6020.71
2025-01-13KALV-0.555.6021.48
2025-01-14KALV-0.555.6021.48
2025-01-15KALV-0.555.6021.48
2025-01-16KALV-0.565.6021.35
2025-01-17KALV-0.565.6021.35
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.91

Avg. EPS Est. Current Quarter

-0.88

Avg. EPS Est. Next Quarter

-0.92

Insider Transactions

-0.56

Institutional Transactions

5.6

Beta

0.85

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

5

Growth Score

21

Sentiment Score

4

Actual DrawDown %

81.6

Max Drawdown 5-Year %

-90.1

Target Price

27.88

P/E

Forward P/E

PEG

P/S

P/B

2.68

P/Free Cash Flow

EPS

-3.64

Average EPS Est. Cur. Y​

-3.64

EPS Next Y. (Est.)

-2.78

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.76

Return on Equity vs Sector %

-135.8

Return on Equity vs Industry %

-123.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.68

EBIT Estimation

KalVista Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 150
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
stock quote shares KALV – KalVista Pharmaceuticals Inc Stock Price stock today
news today KALV – KalVista Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch KALV – KalVista Pharmaceuticals Inc yahoo finance google finance
stock history KALV – KalVista Pharmaceuticals Inc invest stock market
stock prices KALV premarket after hours
ticker KALV fair value insiders trading